Total lesion glycolysis determined per RECIST 1.1 criteria predicts survival in EGFR mutation-negative patients with advanced lung adenocarcinoma

Tsung Ying Ho, Pai Chien Chou, Cheng Ta Yang, Ngan Ming Tsang, Tzu Chen Yen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: The aim of this retrospective study was to investigate the clinical impact of 18F-FDG PET in patients with advanced lung adenocarcinoma stratified according to the epidermal growth factor receptor (EGFR) mutation status. Patients and Methods: A total of 56 patients with advanced lung adenocarcinoma were included in the study. Thirty-one patients (55%) were EGFR mutation-positive, whereas the remaining 25 (45%) participants tested negative for EGFR mutations. All of the patients underwent 18F-FDG PET/CT for pretreatment planning. The main outcome measure was overall survival (OS) at 24 months. The following 18F-FDG PET/CT-derived variables were tested for their associations with OS: main tumor SUV max, main tumor total lesion glycolysis, and target lesions TLG determined per RECIST (Response Evaluation Criteria In Solid Tumors) 1.1 criteria (TLGRECIST). We also investigated the clinical characteristics in relation to OS and EGFR mutation status. Results: In EGFR mutation-positive patients, neither the clinical characteristics nor 18F-FDG PET/CT-derived parameters were significantly associated with OS. In contrast, univariate analysis identified male sex, a positive history of smoking, and TLGRECIST greater than or equal to 412 g as adverse prognostic factors for OS in EGFR mutation-negative patients. After adjustment for potential confounders in multivariate analysis, TLGRECIST was the sole independent predictor of OS in this subgroup. Conclusions: TLG determined per RECIST 1.1 criteria is an independent predictor of OS in EGFR mutation-negative patients with advanced lung adenocarcinoma. Further studies are needed to investigate whether this parameter may be a promising tool for stratifying such patients for risk-adapted therapies.

Original languageEnglish
Pages (from-to)e295-e299
JournalClinical Nuclear Medicine
Volume40
Issue number6
DOIs
Publication statusPublished - Jun 25 2015
Externally publishedYes

Fingerprint

Glycolysis
Epidermal Growth Factor Receptor
Mutation
Survival
Fluorodeoxyglucose F18
Response Evaluation Criteria in Solid Tumors
Adenocarcinoma of lung
Neoplasms
Multivariate Analysis
Retrospective Studies
Smoking
Outcome Assessment (Health Care)

Keywords

  • F-FDG PET
  • adenocarcinoma
  • epidermal growth factor receptor mutations
  • lung cancer
  • RECIST 1.1
  • total lesion glycolysis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Total lesion glycolysis determined per RECIST 1.1 criteria predicts survival in EGFR mutation-negative patients with advanced lung adenocarcinoma. / Ho, Tsung Ying; Chou, Pai Chien; Yang, Cheng Ta; Tsang, Ngan Ming; Yen, Tzu Chen.

In: Clinical Nuclear Medicine, Vol. 40, No. 6, 25.06.2015, p. e295-e299.

Research output: Contribution to journalArticle

@article{8b8805a825fd45f4a2e14ec1d8b7c255,
title = "Total lesion glycolysis determined per RECIST 1.1 criteria predicts survival in EGFR mutation-negative patients with advanced lung adenocarcinoma",
abstract = "Objective: The aim of this retrospective study was to investigate the clinical impact of 18F-FDG PET in patients with advanced lung adenocarcinoma stratified according to the epidermal growth factor receptor (EGFR) mutation status. Patients and Methods: A total of 56 patients with advanced lung adenocarcinoma were included in the study. Thirty-one patients (55{\%}) were EGFR mutation-positive, whereas the remaining 25 (45{\%}) participants tested negative for EGFR mutations. All of the patients underwent 18F-FDG PET/CT for pretreatment planning. The main outcome measure was overall survival (OS) at 24 months. The following 18F-FDG PET/CT-derived variables were tested for their associations with OS: main tumor SUV max, main tumor total lesion glycolysis, and target lesions TLG determined per RECIST (Response Evaluation Criteria In Solid Tumors) 1.1 criteria (TLGRECIST). We also investigated the clinical characteristics in relation to OS and EGFR mutation status. Results: In EGFR mutation-positive patients, neither the clinical characteristics nor 18F-FDG PET/CT-derived parameters were significantly associated with OS. In contrast, univariate analysis identified male sex, a positive history of smoking, and TLGRECIST greater than or equal to 412 g as adverse prognostic factors for OS in EGFR mutation-negative patients. After adjustment for potential confounders in multivariate analysis, TLGRECIST was the sole independent predictor of OS in this subgroup. Conclusions: TLG determined per RECIST 1.1 criteria is an independent predictor of OS in EGFR mutation-negative patients with advanced lung adenocarcinoma. Further studies are needed to investigate whether this parameter may be a promising tool for stratifying such patients for risk-adapted therapies.",
keywords = "F-FDG PET, adenocarcinoma, epidermal growth factor receptor mutations, lung cancer, RECIST 1.1, total lesion glycolysis",
author = "Ho, {Tsung Ying} and Chou, {Pai Chien} and Yang, {Cheng Ta} and Tsang, {Ngan Ming} and Yen, {Tzu Chen}",
year = "2015",
month = "6",
day = "25",
doi = "10.1097/RLU.0000000000000774",
language = "English",
volume = "40",
pages = "e295--e299",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Total lesion glycolysis determined per RECIST 1.1 criteria predicts survival in EGFR mutation-negative patients with advanced lung adenocarcinoma

AU - Ho, Tsung Ying

AU - Chou, Pai Chien

AU - Yang, Cheng Ta

AU - Tsang, Ngan Ming

AU - Yen, Tzu Chen

PY - 2015/6/25

Y1 - 2015/6/25

N2 - Objective: The aim of this retrospective study was to investigate the clinical impact of 18F-FDG PET in patients with advanced lung adenocarcinoma stratified according to the epidermal growth factor receptor (EGFR) mutation status. Patients and Methods: A total of 56 patients with advanced lung adenocarcinoma were included in the study. Thirty-one patients (55%) were EGFR mutation-positive, whereas the remaining 25 (45%) participants tested negative for EGFR mutations. All of the patients underwent 18F-FDG PET/CT for pretreatment planning. The main outcome measure was overall survival (OS) at 24 months. The following 18F-FDG PET/CT-derived variables were tested for their associations with OS: main tumor SUV max, main tumor total lesion glycolysis, and target lesions TLG determined per RECIST (Response Evaluation Criteria In Solid Tumors) 1.1 criteria (TLGRECIST). We also investigated the clinical characteristics in relation to OS and EGFR mutation status. Results: In EGFR mutation-positive patients, neither the clinical characteristics nor 18F-FDG PET/CT-derived parameters were significantly associated with OS. In contrast, univariate analysis identified male sex, a positive history of smoking, and TLGRECIST greater than or equal to 412 g as adverse prognostic factors for OS in EGFR mutation-negative patients. After adjustment for potential confounders in multivariate analysis, TLGRECIST was the sole independent predictor of OS in this subgroup. Conclusions: TLG determined per RECIST 1.1 criteria is an independent predictor of OS in EGFR mutation-negative patients with advanced lung adenocarcinoma. Further studies are needed to investigate whether this parameter may be a promising tool for stratifying such patients for risk-adapted therapies.

AB - Objective: The aim of this retrospective study was to investigate the clinical impact of 18F-FDG PET in patients with advanced lung adenocarcinoma stratified according to the epidermal growth factor receptor (EGFR) mutation status. Patients and Methods: A total of 56 patients with advanced lung adenocarcinoma were included in the study. Thirty-one patients (55%) were EGFR mutation-positive, whereas the remaining 25 (45%) participants tested negative for EGFR mutations. All of the patients underwent 18F-FDG PET/CT for pretreatment planning. The main outcome measure was overall survival (OS) at 24 months. The following 18F-FDG PET/CT-derived variables were tested for their associations with OS: main tumor SUV max, main tumor total lesion glycolysis, and target lesions TLG determined per RECIST (Response Evaluation Criteria In Solid Tumors) 1.1 criteria (TLGRECIST). We also investigated the clinical characteristics in relation to OS and EGFR mutation status. Results: In EGFR mutation-positive patients, neither the clinical characteristics nor 18F-FDG PET/CT-derived parameters were significantly associated with OS. In contrast, univariate analysis identified male sex, a positive history of smoking, and TLGRECIST greater than or equal to 412 g as adverse prognostic factors for OS in EGFR mutation-negative patients. After adjustment for potential confounders in multivariate analysis, TLGRECIST was the sole independent predictor of OS in this subgroup. Conclusions: TLG determined per RECIST 1.1 criteria is an independent predictor of OS in EGFR mutation-negative patients with advanced lung adenocarcinoma. Further studies are needed to investigate whether this parameter may be a promising tool for stratifying such patients for risk-adapted therapies.

KW - F-FDG PET

KW - adenocarcinoma

KW - epidermal growth factor receptor mutations

KW - lung cancer

KW - RECIST 1.1

KW - total lesion glycolysis

UR - http://www.scopus.com/inward/record.url?scp=84929903790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929903790&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000000774

DO - 10.1097/RLU.0000000000000774

M3 - Article

C2 - 25783515

AN - SCOPUS:84929903790

VL - 40

SP - e295-e299

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 6

ER -